Premium
The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression
Author(s) -
Sauer Heinrich,
Kampmann Henning,
Khosravi Farhad,
Sharifpanah Fatemeh,
Wartenberg Maria
Publication year - 2021
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13452
Subject(s) - nicotinamide phosphoribosyltransferase , biology , abcg2 , cell growth , cancer research , cancer cell , pharmacology , nad+ kinase , biochemistry , atp binding cassette transporter , cancer , transporter , enzyme , gene , genetics
Abstract Nicotinamide phosphoribosyltransferase (NAMPT) is a rate‐limiting enzyme for nicotinamide adenine dinucleotide (NAD) synthesis and is involved in cancer cell proliferation through regulation of energy production pathways. Therefore, NAMPT inhibitors are promising drugs for cancer therapy by limiting energy supply of tumours. Herein, we demonstrated that the NAMPT inhibitor FK866 ((E)‐N‐(4‐(1‐Benzoylpiperidin‐4‐yl)butyl)‐3‐(pyridin‐3‐yl)acrylamide) dose‐dependently inhibited growth and cell motility of DU‐145 prostate tumour spheroids and decreased the intracellular ATP concentration. The apoptosis marker cleaved caspase‐3 remained unchanged, but the autophagy marker microtubule‐associated protein 1A/1B‐light chain 3 (LC3) was upregulated. Growth inhibition was reversed upon co‐administration of NAD to the cell culture medium. FK866 decreased calcein as well as pheophorbide A efflux from tumour spheroids and increased doxorubicin toxicity, indicating interference with function of drug efflux transporters. DU‐145 multicellular tumour spheroids expressed the stem cell associated markers CD133, CD44, Oct4, Nanog, Sox2, and drug transporters ABCB1, ABCG2, and ABCC1 which are associated with stem cell properties in cancer cells. The ABCB1 inhibitor zosuquidar, the ABCG2 inhibitor Ko143, and the ABCC1 inhibitor MK571 increased calcein retention. Neither protein expression of stem cell markers, nor drug transporters was significantly changed upon FK866 treatment. In conclusion, our data suggest that FK866 inhibits prostate cancer cell proliferation by interference with the energy metabolism, and function of drug efflux transporters.